Deletion of Crry, the murine ortholog of the sporadic Alzheimer's disease risk gene CR1, impacts tau phosphorylation and brain CFH

[1]  Thomas W. Mühleisen,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.

[2]  G. Bu.  ApoE and apoE receptors in brain lipid metabolism and AD , 2012, Molecular Neurodegeneration.

[3]  R. Guerreiro,et al.  Complement receptor 1 (CR1) and Alzheimer's disease. , 2012, Immunobiology.

[4]  T. Hughes,et al.  C3-dependent mechanism of microglial priming relevant to multiple sclerosis , 2012, Proceedings of the National Academy of Sciences.

[5]  K. Morgan,et al.  The three new pathways leading to Alzheimer's disease , 2011, Neuropathology and applied neurobiology.

[6]  F. Pasquier,et al.  Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites , 2011, Molecular Psychiatry.

[7]  Holly Soares,et al.  Meta-Analysis for Genome-Wide Association Study Identifies Multiple Variants at the BIN1 Locus Associated with Late-Onset Alzheimer's Disease , 2011, PloS one.

[8]  Susan M Resnick,et al.  Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. , 2010, Archives of general psychiatry.

[9]  J. Trojanowski,et al.  Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies , 2009, Nature Reviews Drug Discovery.

[10]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[11]  Nick C Fox,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes , 2009, Nature Genetics.

[12]  S. Lovestone,et al.  Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice , 2009, Biochemical and biophysical research communications.

[13]  John Hardy,et al.  The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal , 2009, Journal of neurochemistry.

[14]  T. Hughes,et al.  Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury. , 2009, Molecular immunology.

[15]  Eileen Daly,et al.  Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer’s disease , 2008, Journal of Neurology.

[16]  S. Lovestone,et al.  Proteome-based plasma biomarkers for Alzheimer's disease. , 2006, Brain : a journal of neurology.

[17]  J. Kuret,et al.  Pseudophosphorylation and Glycation of Tau Protein Enhance but Do Not Trigger Fibrillization in Vitro* , 2004, Journal of Biological Chemistry.

[18]  I. Grundke‐Iqbal,et al.  Promotion of Hyperphosphorylation by Frontotemporal Dementia Tau Mutations* , 2004, Journal of Biological Chemistry.

[19]  J. Cho,et al.  Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3β (GSK3β) plays a critical role in regulating tau's ability to bind and stabilize microtubules , 2003, Journal of neurochemistry.

[20]  R. Strohmeyer,et al.  Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer's disease brain , 2002, Journal of Neuroimmunology.

[21]  M. Emmerling,et al.  The role of complement in Alzheimer's disease pathology. , 2000, Biochimica et biophysica acta.

[22]  B. Palanca,et al.  A critical role for murine complement regulator crry in fetomaternal tolerance. , 2000, Science.

[23]  Khadija Iqbal,et al.  Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. , 1998, Archives of biochemistry and biophysics.

[24]  Alejandra del C. Alonso,et al.  Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules , 1996, Nature Medicine.

[25]  E. Mandelkow,et al.  Cell cycle-dependent phosphorylation and microtubule binding of tau protein stably transfected into Chinese hamster ovary cells. , 1995, Molecular biology of the cell.

[26]  S. Adler,et al.  Complement regulation in the rat glomerulus: Crry and CD59 regulate complement in glomerular mesangial and endothelial cells. , 1995, Kidney international.

[27]  P. Cohen,et al.  Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. , 1994, The Biochemical journal.

[28]  E. Mandelkow,et al.  Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: Distinction between PHF-like immunoreactivity and microtubule binding , 1993, Neuron.

[29]  T. Kinoshita,et al.  Ligand specificities of mouse complement receptor types 1 (CR1) and 2 (CR2) purified from spleen cells. , 1993, International immunology.

[30]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[31]  V. Holers,et al.  Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1 , 1992, The Journal of experimental medicine.

[32]  V. Holers,et al.  A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2. , 1990, Journal of immunology.

[33]  S. Christensen,et al.  The murine complement receptor gene family. IV. Alternative splicing of Cr2 gene transcripts predicts two distinct gene products that share homologous domains with both human CR2 and CR1. , 1990, Journal of immunology.

[34]  M. Aegerter,et al.  Murine complement receptor gene family. II. Identification and characterization of the murine homolog (Cr2) to human CR2 and its molecular linkage to Crry. , 1989, Journal of immunology.

[35]  H. Kozono,et al.  Monoclonal antibodies to mouse complement receptor type 1 (CR1). Their use in a distribution study showing that mouse erythrocytes and platelets are CR1-negative. , 1988, Journal of immunology.

[36]  Nick C Fox,et al.  Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .

[37]  T. Poulos,et al.  Aspartate residue 7 in amyloid β-protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis , 1997, Nature Medicine.

[38]  J. Hardy,et al.  Amyloid deposition as the central event in the aetiology of Alzheimer's disease. , 1991, Trends in pharmacological sciences.

[39]  J. Strominger,et al.  Identification of murine complement receptor type 2. , 1989, Proceedings of the National Academy of Sciences of the United States of America.